A Phase 3 Study of Tarlatamab Versus Standard Treatment in People With Small Cell Lung Cancer That Came Back After Platinum-Based Initial Chemotherapy


Full Title

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (WIRB)


The standard treatment for small cell lung cancer (SCLC) that comes back after initial treatment is lurbinectedin or topotecan. Examples of platinum-based chemotherapy are cisplatin and carboplatin. They are often the first chemotherapy drugs given to people with SCLC.

Researchers want to see if tarlatamab is better than lurbinectedin or topotecan in people with SCLC that came back. If you join this study, you will get either tarlatamab or standard chemotherapy (lurbinectedin or topotecan). Tarlatamab and lurbinectedin are given intravenously (by vein). Topotecan is taken orally (by mouth) or is given intravenously.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have SCLC that came back after initial platinum-based chemotherapy.
  • Have completed previous treatment at least 3 weeks before getting the study therapy.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Noura Choudhury’s office at 646-946-6398.




Phase III (phase 3)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID